SCHEMBL3244264

SCHEMBL3244264

COc1cc(NC(=O)c2ccc3c(c2)OCO3)ccc1NS(C)(=O)=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 11/20 0.67
▸ MAPT P10636 7/20 0.66
▸ KDM4E B2RXH2 4/20 0.66
▸ HPGD P15428 1/20 0.66
▸ NPC1 O15118 10/20 0.65
▸ SMN1; SMN2 Q16637 6/20 0.65
▸ TP53 P04637 2/20 0.65
▸ PKM P14618 2/20 0.65
▸ ALDH1A1 P00352 2/20 0.65
▸ GAA P10253 1/20 0.65
▸ HSD17B10 Q99714 1/20 0.65
▸ NFKB1 P19838 1/20 0.60
▸ NFKB2 Q00653 1/20 0.60
▸ RELA Q04206 1/20 0.60
▸ CASP3 P42574 1/20 0.60
▸ SENP7 Q9BQF6 1/20 0.60
▸ IMPDH2 P12268 1/20 0.59
▸ MAOB P27338 1/20 0.59
▸ MEN1 O00255 1/20 0.58
▸ KMT2A Q03164 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3234337 0.96 RAB9A (0.72) RAB9AMAPTKDM4EHPGDNPC1
SCHEMBL3241511 0.92 RAB9A (0.69) RAB9AMAPTKDM4EHPGDNPC1
SCHEMBL3245157 0.86 ALDH1A1 (0.60) RAB9AMAPTKDM4EHPGDNPC1
SCHEMBL3245109 0.83 ALDH1A1 (0.60) RAB9AMAPTKDM4EHPGDNPC1
SCHEMBL3241519 0.81 ALDH1A1 (0.58) RAB9AMAPTKDM4EHPGDNPC1
SCHEMBL13293346 0.80 ALDH1A1 (0.54) RAB9AMAPTHPGDNPC1SMN1; SMN2
SCHEMBL13293317 0.80 ALDH1A1 (0.57) RAB9AMAPTKDM4ENPC1SMN1; SMN2
SCHEMBL27179885 0.78 ALDH1A1 (0.66) RAB9AMAPTKDM4EHPGDNPC1
SCHEMBL5502346 0.77 ALDH1A1 (0.51) RAB9AMAPTKDM4ENPC1SMN1; SMN2
SCHEMBL108116 0.77 NPC1 (1.00) RAB9AMAPTNPC1SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745490-B2 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTEOTECH, INC. (US) 2010-06-29 — — US disclosed
US-7745490-B2 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTEOTECH, INC. (US) 2010-06-29 — — US disclosed
US-7745490-B2 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTEOTECH, INC. (US) 2010-06-29 — — US disclosed
EP-1751097-B1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC (US) 2009-12-30 — — EP disclosed
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2009-03-05 — — US disclosed
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2009-03-05 — — US disclosed
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2009-03-05 — — US disclosed
EP-1751097-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES Proteotech, Inc. (US) 2007-02-14 — — EP disclosed
US-20060199838-A1 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTAMED, INC. 2006-09-07 — — US disclosed
WO-2005113489-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH, INC. (US) 2005-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES IAPP, SNCA, BACE2 RAB9A 2958/4885MAPT 40/4885KDM4E 3095/4885
US-20060199838-A1 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies IAPP, SNCA, BACE2 RAB9A 2893/4885MAPT 25/4885KDM4E 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback